Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K. D., Tursi, J., Blackhall, F., & Louis, R. (Other coll.). (04 December 2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
New England Journal of Medicine, 371 (23), 2167-77. doi:10.1056/NEJMoa1408440
https://hdl.handle.net/2268/176692